To read the full story
Related Article
- Kyowa Kirin’s Phozevel Now Available for Hyperphosphatemia
February 20, 2024
- GSK’s Arexvy Hits Market as Japan’s 1st RSV Vaccine
January 15, 2024
- Phesgo, Epkinly, Leqvio Hit Japan Market, Wegovy Launch Set for Feb. 22
November 24, 2023
- 1st G-Lasta Biosimilar Gets Japan Listing, Stelara Follow-On Not on Roster
November 21, 2023
- Listing OK’ed for Phesgo, Leqvio, Epkinly, and More; 30 Billion-Plus Yen Peak Sales for 3 Meds
November 16, 2023
- Japan Panel Clears GSK’s Arexvy, 1st RSV Vaccine, for Approval
August 29, 2023
- Japan Panel OKs Novartis’ siRNA Dyslipidemia Therapy and More
August 22, 2023
- Perjeta/Herceptin SC Combo, 1st Stelara, G-Lasta Biosimilars in Line for Japan Approval
August 1, 2023
REGULATORY
- MHLW Flags Risk of Eye Disorders Associated with Tivdak upon Approval
March 31, 2025
- Daisuke Koga Named Head of PMDA’s International Office
March 31, 2025
- AMED Ties Up with Korea’s Govt Backed Research Institute
March 31, 2025
- Sakigake Tag Withdrawn for Boehringer, AbbVie APIs
March 31, 2025
- Japan Jittery over Mass Layoffs at FDA, though HHS Says Reviewers Won’t Be Affected
March 31, 2025
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…